Skip to main content

Table 2 Demographic and treatment plan-related data

From: Dose-escalation using intensity-modulated radiotherapy for prostate cancer - evaluation of quality of life with and without 18F-choline PET-CT detected simultaneous integrated boost

  prostate with SIB (n = 46) prostate only (n = 21)
patient age/years
median (range)
72 (59-83) 71 (61-81)
PTVprostate /cc
median (range)
142 (35-310) 163 (70-537)
PTVboost /cc
median (range)
17 (4-46) -
% PSA ≤10 ng/mL 74% 76%
% Gleason score ≤6 65% 71%
% T-stage ≤2a 78% 86%
% NHT 17% 19%
bladder volume/cc
median (range)
237 (69-645) 225 (98-493)
rectum volume/cc
median (range)
88 (36-235) 81 (48-252)
EUD PTVprostate*/Gy
median (range)
76.7 (73.8-78.3) 76.0 (74.3-77.1)
EUD PTVboost /Gy
median (range)
79.5 (76.6-80.5) -
EUD bladder/Gy
median (range)
55.6 (41.7-63.2) 54.6 (45.0-62.3)
EUD rectum/Gy
median (range)
55.9 (47.1-62.4) 54.6 (40.1-60.6)
NTCP bladder/%
median (range)
0 (0-0.6) 0 (0-0.4)
NTCP rectum/%
median (range)
6.9 (2.2-14.7) 5.5 (1.5-11.2)
  1. Abbreviations: PTV = planning treatment volume; PSA = prostate-specific antigen; NHT = neoadjuvant hormonal therapy; EUD = equivalent uniform dose; NTCP = normal tissue complication probability
  2. *p < 0.01